GLP-1 drugs may skew PET/CT scan results
At the European Association of Nuclear Medicine Congress in Barcelona this week, researchers reported that patients taking GLP-1 agonists such as Ozempic, Wegovy, Mounjaro and Zepbound showed atypical tracer uptake patterns on cancer PET/CT scans that could be misread as disease. Led by Dr. Peter Strouhal of Alliance Medical Ltd. (UK), the case review advises imaging teams to account for GLP-1 use when interpreting scans; the authors do not recommend stopping medication and plan to collect more data from global centers.
Health
Science
đ Key Facts
- Case review presented at the 38th EANM Congress found atypical PET/CT uptake in GLP-1 users
- Lead author: Dr. Peter Strouhal (Alliance Medical Ltd., UK) says no current guidance addresses this pattern
- Researchers advise against stopping GLP-1s before scans but urge imaging teams to consider medication use; U.S. clinicians note FDG tracer uptake may be affected by altered glucose metabolism